Securus Technologies highlights GTL’s inaccurate statements

Richard Smith is the current CEO of Securus Technologies. He spoke in a recent press release stating wrongdoings undertaken by GTL. He stated his disappointed stating that he never thought GTL could go to such levels. Even though GTL has the responsibility of making money, it deserves to act in the best of customers. GTL has not acted according to integrity. Securus Technologies released a subsequent report that highlighted GTL’s wrongdoings and corrects its inaccuracies. GTL has acted in several wrongdoings in the past. Securus indicated that Global Tel Link adjusted their phones so as to record additional time on calls. The company charged higher rates than the industry set standards. Another wrongdoing performed by the company was that it practiced its customers more than once.

 

Securus stated that the release of wrongdoings is just the beginning. The firm stated that the company is set to release additional findings in the coming weeks. Securus Technologies noted that GTL has always published wrong information on their website. GTL released information recently where it stated that Securus Technologies had infringed its patent rights. Securus Technologies has since come out to state that GTL did not have any mentioned patents or innovations.

 

GTL made another claim stating that the U.S. Appeals Board has allowed them to use their PTAB patent. The firm went further to indicate that it was seeking for damages when Securus used its patents. However, Securus has come out to state that all those allegations were wrong.

 

Securus Technologies is a leader in the criminal, civil, and justice department. The company has availed its services to thousands of correction facilities in the entire United States.

 

The Business Ventures of Alexei and his Philanthropy in Russia

Alexei Beltyukov is recognized as a successful businessperson who has established many companies in Russia, which is his home country. He first studied medicine, but he chose to pursue business. Mr. Beltyukov acquired his excellent business skills from the INSTEAD University.

The learning institution is based in France. He is a member of the INSTEAD Russian Alumni Scholarship and has been offering scholarships to Russian students who join the University. The firms that he has established include Endemic Capital that was created in 2013 with a primary goal of supporting the activities of Russian startups.

Another company that he founded is that A-Ventures and its main service was to assist unstable companies by offering them financial aid. He was its managing partner from the time it was established in 2007 to 2014 when it was sold. His philanthropic activities have significantly assisted the people of Russia.

The entrepreneur started gaining interest in natural gas in 2006. He founded New Gas Technologies, which focused on the industrial use of the commodity. Alexei is currently serving the FORO. The company deals with the manufacture and commercialization of laser energy and how it can be of great importance in the mining, geothermal, natural gas, and oil industries. He observes the board of the company.

Beltyukov has been working for the Russian government since January 2011. He was employed to serve as the vice president of the Skolkovo Foundation, and his principal obligation there was to offer economic guidance. The organization’s primary function is to provide resources and business platforms to the Russian people who needed to create IT enterprises.

In 2004, Alexei Beltyukov founded a noteworthy enterprise that is known as SOLVY. The firm offers a dependable opportunity for students to learn hard subjects on their own as well as interact with their tutors. The learners can study over the internet while being supervised by the teachers. SOLVY has been making it easy for children to understand hard subjects like mathematics.

Dr. Mikhail Blagosklonny is an Authority in Cancer and Life-extension Research

Dr. Mikhail Blagosklonny is a world’s prominent oncologist and a researcher. He is experienced in cancer research on Impactjournals.com and works as a professor at the New York-based Roswell Park Cancer Institute. His brilliant works are recognized within and outside the United States.

Academics and professional expertise

Dr. Blagosklonny became a senior researcher and tutor at Roswell Park Cancer Institute New York in 2009. His appointment came after the Institute reviewed his extensive work experience gained from working with both colleges and other research institutes. He has an M.D in internal medicine and Ph.D. in cardiology and experimental medicine.
Upon completion of his higher studies, Dr. Blagosklonny was called upon to serve as an associate professor at New York Medical College. He taught all medical students at the college. In 2002, he was appointed as the senior scientist at Ordway Research Institute headquartered in Albany, New York. This position allowed Dr. Blagosklonny to focus on his life extension research on impactjournals.com.

Dr. Blagosklonny’s interests and research hypothesis

Dr. Blagosklonny research interests are remarkable; they include cancer, aging, targeted cancer therapies that protect normal cells from cancerous ones, and anti-aging drugs. He has made big strides in research world by formulating a hypothesis in the significance of TOR Signaling in aging and cancer. Dr. Mikhail Blagosklonny proposed that Rapamycin, a popular cancer drug, might be used to extend life. He has held this concept for years, and he hopes to prove it in the future.

Editorial activities

Dr. Blagosklonny is the founder and chief editor of Oncotarget. Oncotarget is a peer-reviewed medical journal covering all areas of aging and oncology. Dr. Blagosklonny co-founded Oncotarget together with Andrei Gudkov in 2010. This journal is the leading open-access oncology journal in the United States. Additionally, he edits other journals such as Cancer Biology & Therapy. Dr. Blagosklonny also serves on the editorial board of Cell Death & Differentiation. He has authored over 270 papers with over 250,000 citations.

Reference: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531